Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 3/20 | 0.33 |
| ▸ | KDR | P35968 | 3/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL589530 | 0.84 | AGBL2 (0.34) | BACE1ALDH1A1KDM4E | |
| SCHEMBL5797778 | 0.79 | ACACB (0.34) | ACACBBACE1DYRK1ADYRK1B | |
| SCHEMBL29465147 | 0.79 | DGAT1 (0.35) | ACACBBACE1DYRK1ADYRK1BALDH1A1 | |
| SCHEMBL10081962 | 0.79 | DGAT1 (0.35) | ACACBBACE1DYRK1ADYRK1BALDH1A1 | |
| SCHEMBL15543442 | 0.74 | NPSR1 (0.41) | — | |
| SCHEMBL31231846 | 0.74 | NPSR1 (0.41) | — | |
| SCHEMBL16978524 | 0.74 | CFTR (0.40) | BACE1KDM4ENPC1 | |
| SCHEMBL1661495 | 0.73 | KDM4E (0.42) | BACE1DYRK1BALDH1A1KDM4ENPC1 | |
| SCHEMBL17224823 | 0.72 | GSK3B (0.37) | ACACBBACE1ALDH1A1KDM4E | |
| SCHEMBL5801610 | 0.72 | DGAT1 (0.53) | ACACBKDRALDH1A1EPHX1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150065516-A1 | NEW BIARYL AMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150065516-A1 | NEW BIARYL AMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150065516-A1 | NEW BIARYL AMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2015-03-05 | — | — | US | disclosed |
| US-8912221-B2 | Biaryl amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912221-B2 | Biaryl amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912221-B2 | Biaryl amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-12-16 | — | — | US | disclosed |
| EP-2658848-A1 | NEW BIARYL AMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-11-06 | — | — | EP | disclosed |
| EP-1893579-B1 | 1-HYDROXYCYCLOALKANECARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-05-01 | — | — | EP | disclosed |
| WO-2012089601-A1 | NEW BIARYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-05 | — | — | WO | disclosed |
| US-20120165338-A1 | NEW BIARYL AMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-06-28 | — | — | US | disclosed |
| US-20120165338-A1 | NEW BIARYL AMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-06-28 | — | — | US | disclosed |
| US-20120165338-A1 | NEW BIARYL AMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-06-28 | — | — | US | disclosed |
| US-7816380-B2 | 1-hydroxycycloalkanecarboxamide derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7790754-B2 | Alpha-hydroxy amides as bradykinin antagonists or inverse agonists | MERCK SHARP & DOHME CORP. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1706372-B1 | ALPHA-HYDROXY AMIDES AS BRADYKININ ANTAGONISTS OR INVERSE AGONISTS | MERCK SHARP & DOHME (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20090062349-A1 | 1-Hydroxycycloalkanecarboxamide derivatives | MERCK SHARP & DOHME LLC | 2009-03-05 | — | — | US | disclosed |
| US-20080318976-A1 | Alpha-Hydroxy Amides as Bradykinin Antagonists or Inverse Agonists | MERCK SHARP & DOHME CORP. | 2008-12-25 | — | — | US | disclosed |
| WO-2006052514-A1 | ASYMMETRIC HYDROGENATION OF ENAMIDES | MERCK & CO., INC. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065516-A1 | NEW BIARYL AMIDE DERIVATIVES | BICRA, HDAC10, BRD7 | ACACB 1996/4885EGFR 638/4885KDR 872/4885 |
| US-20080318976-A1 | Alpha-Hydroxy Amides as Bradykinin Antagonists or Inverse Agonists | BDKRB1, BDKRB2, HCAR2 | ACACB 2636/4885EGFR 1673/4885KDR 288/4885 |
| US-20090062349-A1 | 1-Hydroxycycloalkanecarboxamide derivatives | BDKRB1, BDKRB2, HRH4 | ACACB 3488/4885EGFR 699/4885KDR 450/4885 |
| US-20120165338-A1 | NEW BIARYL AMIDE DERIVATIVES | BICRA, HDAC10, BRD7 | ACACB 1996/4885EGFR 638/4885KDR 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.